TORCH: Phase II study to determine the safety and efficacy of the dual mTORC inhibitor AZD2014 and to investigate additional toxicities in combination with rituximab in relapsed refractory DLBCL

  • Fenwick, Nicola (Principal Investigator)

Project Details

Short titleTORCH: Phase II study to determine the safety and efficacy of the dual mTORC inhibitor AZD2014 and to investigate additional toxicities in combination with rituximab in relapsed refractory DLBCL
StatusFinished
Effective start/end date1/08/15 → 31/03/21

Funding

  • BLOODWISE
  • ASTRA ZENECA UK LIMITED